The drug, called Sulfanegen, quickly converts cyanide in the body into a less toxic compound. Researchers at the University of Minnesota are developing a new antidote that could give first responders a crucial edge in saving those exposed to cyanide poisoning. During an emergency, that limits how many other people can be treated before it’s too late. Unfortunately, cyanide antidotes on the market today require at least 15 minutes of an IV drip. Fast treatment can mean the difference between life and death.
About the International Institute for Biosensing.Research Infrastructure Investment Program.Hosting International Visitors, Scholars & Researchers.Conflicts of Commitment/Interest & Foreign Talent Recruitment Programs.Disclosing Foreign Support to Federal Science Agencies.International Research Support & Guidance.BSL-3/ABSL-3 Research Laboratory Suites.The Office of Research Information Systems.Louis Stokes North Star STEM Alliance/MnDRIVE Partnership.Research Integrity & Safety Collaborative (RISC).Council of Research Associate Deans (CRAD).Office of the Vice President for Research.Presented in part at American College of Emergency Physicians, October 2017.
Lewis was an employee of Pfizer/Viatris at the time of research and manuscript writing. Sanders is an employee of Pfizer and Drew E. Donna Dalton is an employee of Syneos Health who was a paid contractor to Pfizer in connection with this study. Kahn was an employee of University of South Alabama Medical Center, Arnold Luterman Regional Burn Center during the time of the research and is now an employee at the Medical University of South Carolina, and was a consultant to Pfizer in connection with this study. Michalopoulos was an employee of Open Health during the time of the research and was a paid consultant to Pfizer in connection with this study. Jennifer M Stephens owns Open Health stock. Stephens and Jyoti Aggarwal are employees of Open Health who were paid consultants to Pfizer in connection with this study. All rights reserved.Ĭonflict of interest statement This study was sponsored by Pfizer. Use of hydroxocobalamin in patients with known or suspected cyanide poisoning from closed-space fire smoke inhalation may decrease hospital costs and contribute to more efficient healthcare resource utilization.Ĭlosed-space fire Cyanide Economic burden Hydroxocobalamin Inhalation injury.Ĭopyright © 2022 The Authors. A univariate sensitivity analysis demonstrated that the most impactful variables in the cost analysis were related to hospital length of stay (ICU followed by non-ICU stay), followed by the daily cost of ICU stay. Costs attributed to mechanical ventilation also decreased with use of hydroxocobalamin. The most substantive cost-savings resulted from decreased hospital length of stay (i.e., intensive care unit and non-ICU). Use of hydroxocobalamin reduces healthcare resource utilization and contributes to decreased per-patient hospital costs ($15,381 with hydroxocobalamin treatment versus $22,607 with no cyanide antidote). All costs were reported in 2017 US dollars. Deterministic sensitivity analysis was performed to identify the most influential model parameters. A cost-to-charge ratio was applied so that all costs would reflect hospital costs rather than hospital charges. Outcomes reported in the analysis included expected healthcare resource utilization in the US population and per-patient costs with and without the use of hydroxocobalamin. Epidemiologic parameters and costs were estimated from the published literature, and publicly-available hospital charges were identified. Healthcare resource utilization was estimated from a retrospective evaluation of clinical outcomes in hydroxocobalamin-treated patients and in historical controls without hydroxocobalamin use (Nguyen, et al. The aim of this exploratory study was to determine the economic implications of treating patients with known or suspected cyanide poisoning due to smoke inhalation with hydroxocobalamin.Ī decision analysis model was developed from the US hospital perspective. With no point of care cyanide test at the scene of a fire, first responders and clinicians base decisions to treat with cyanide antidote on patient history, clinical signs, and other indirect data points that have not been proven to correspond with actual systemic levels of cyanide. Cyanide poisoning can occur due to exposure to smoke in closed-space fires.
0 kommentar(er)
